Storia in 3 fonti

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

Raccontata da

fiercepharma.com

endpoints.news

pharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

originale

fiercepharma.com1 mese fa

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's…

Contraline raised $92.5M Series B to advance NES/T Gel, a first-in-class topical male contraceptive, into phase 3 trials starting 2027. The round signals VC appetite for consumer-driven healthcare in underserved categories, positioning potential telehealth distribution.

Leggi questa versione →

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Confronto fonti

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's…

Timeline cronologica

Contraline and its male birth control candidate rally $92.5M amid push into 'massive white space' of men's health

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology